Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for Tough-to-Treat cancers: early drug trial seeks participants

NCT ID NCT05978284

Summary

This early-stage study is testing a new drug called ZG006 for people with advanced small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatment options. The main goals are to find the safest and most effective dose and to see how well the drug works against these cancers. Researchers will enroll about 54 adults to receive the experimental treatment and closely monitor their response and any side effects.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, China

Conditions

Explore the condition pages connected to this study.